Wikisage, the free encyclopedia of the second generation, is digital heritage
Iscador: Difference between revisions
Jump to navigation
Jump to search
(link) |
No edit summary |
||
| Line 11: | Line 11: | ||
==Links == | ==Links == | ||
[http://www.pharmawiki.ch/wiki/index.php?wiki=Anthroposophischer%20Mistelextrakt Pharmawiki(de):Mistelextrakt] | *[http://www.pharmawiki.ch/wiki/index.php?wiki=Anthroposophischer%20Mistelextrakt Pharmawiki(de):Mistelextrakt] | ||
*[http://www.whocc.no/atc_ddd_index/?code=L01CZ ATC:L01CZ] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:22, 5 December 2015
Mistletoe (Iskador mali) a preparation of Viscum album L.) off-label. Since decades Mistletoe has been used in European medicine for oncology[1]Mistletoe lectins (e.g. Iscador Q viscotoxin) have been identified as main active components and exhibit cytotoxic effects as well as immunomodulatory activity[2] [3]
Büssing et Ostermann (2012[4]) found some evidence for moderate improvement of quality of life associated with Iscador treatment (Weleda[5]). [6] Pine mistletoe extract (Iscador P Viscum album austriacus) can be used on equine sarcoids as safe and effective treatment.[7]
Links
References
- ↑ Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study
- ↑ Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas
- ↑ Targeting inflammation in cancer-related-fatigue: a rationale for mistletoe therapy as supportive care in colorectal cancer patients
- ↑ Quality of Life and Related Dimensions in Cancer Patients Treated with Mistletoe Extract (Iscador): A Meta-Analysis
- ↑ Iscador Newsletter summer 2015
- ↑ Quality of Life and Neutropenia in Patients with Early Stage Breast Cancer: A Randomized Pilot Study Comparing Additional Treatment with Mistletoe Extract to Chemotherapy Alone
- ↑ Treatment of clinically diagnosed equine sarcoid with a mistletoe extract (Viscum album austriacus)
- ↑ Mistletoe Preparation Iscador: Are there Methodological Concerns with Respect to Controlled Clinical Trials?